Discover Biomedica´s bone biomarker assays

The Biomedica ELISA kits are high-quality assays utilizing characterized epitope mapped antibodies to provide high specificity. These widely cited and easy to use assays come with two controls and with ready to use color coded reagents.

Bone biomarkers are valuable tools that provide insights into bone health, metabolism, and disease status. The use of biomarkers facilitates the diagnosis and treatment of bone diseases and provides a deeper understanding of bone biology. The specific bone biomarkers can reliably be measured in blood samples.

Complete ready to use ELISA kits

User-friendly & reliable.

ELISA kits for clinical & preclinical research

Sclerostin ▪ Dickkopf-1 ▪ Osteoprotegerin ▪ RANKL ▪ FGF23 ▪ Periostin ▪ Semaphorin 4D ▪ LRG ▪ IL-6

• Sclerostin (BI-20492)
• Bioactive Sclerostin (BI-20472)
• DKK-1 (BI-20413)
• OPG (BI-20403)
• RANKL free soluble (BI-20462)
• FGF23 intact (BI-20700)
• FGF23 c-terminal (BI-20702)
• Periostin ELISA (BI-20433)
• Periostin mouse/rat (BI-20433MR)
• SEMA 4D (BI-20405)
• LRG (BI-LRG)
• IL-6 (BI-IL6)

Why chose Biomedica ELISA kits?

• Validated following international quality guidelines
• Normal values provided
• Ready to use calibrators & two controls included
• Small sample volumes
• Widely cited kits in more than 1800 publications

Highly specific ELISA kits that only measure the analyte of interest.

Learn more about some of the novel biomarkers:

Periostin is a soluble extracellular matrix protein that plays a crucial role in bone biology. It is expressed in collagen-rich fibrous connective tissues. Periostin has functions in bone formation, remodeling, tissue repair, oncology, and in various inflammatory settings (1,2).

Leucine-riche alpha-2-glyoprotein (LRG) is a multifunctional protein that has been described in bone diseases. Elevated levels of LRG have been reported in patient with osteoporosis. The specific mechanism on how LRG may impact bone metabolism is not yet fully understood. Researchers are further exploring the potential use of LRG as a prognostic marker in cancer. A recent retrospective study has reported the prognostic value of LRG in breast cancer (3). 

Semaphorin 4D (SEMA4D) is a protein that has been associated with various bone related disorders. Although its involvement in bone regulation is still not fully understood findings suggest a link between Sema4D and estrogen receptor signaling in breast cancer (4).

Fibroblast growth factor-23 (FGF23) is a hormone that plays a crucial role in phosphate homeostasis and vitamin D metabolism. FGF23 is produced by osteocytes, cells that are embedded in the bone matrix. Dysregulation of FGF23 can lead to various bone disorders like X-linked hypophosphatemia (XLH) and tumor induced osteomalacia (TIO) (5, 6).

References

1. Duchamp de Lageneste O, Colnot C. Periostin in bone regeneration. Adv Exp Med Biol. 2019;1132:49-61.
2. Dorafshan S, Razmi M, Safaei S, Gentilin E, Madjd Z, Ghods R. Periostin: biology and function in cancer. Cancer Cell Int. 2022;22(1):315.
3. Zhang YS, Han L, Yang C, Liu YJ, Zhang XM. Prognostic value of lrg1 in breast cancer: a retrospective study. Oncol Res Treat. 2021;44(1-2):36-42.
4. Göbel A, Kuhlmann JD, Link T, et al. Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. J Bone Oncol. 2019;16:100237.
5. Fukumoto S. Fgf23 and bone and mineral metabolism. Handb Exp Pharmacol. 2020;262:281-308.
6. Simic P, Babitt JL. Regulation of fgf23: beyond bone. Curr Osteoporos Rep. 2021;19(6):563-573.